Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28707490 | 0.82 | TSHR (0.39) | ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL11259521 | 0.74 | — | — | |
| SCHEMBL23571 | 0.72 | PDK1 (0.32) | ALDH1A1TSHRTHRBTP53 | |
| SCHEMBL30130704 | 0.71 | — | — | |
| SCHEMBL28102290 | 0.70 | — | — | |
| SCHEMBL9253 | 0.69 | — | — | |
| SCHEMBL6722104 | 0.69 | — | — | |
| SCHEMBL20206689 | 0.69 | PIK3CD (0.34) | POLB | |
| SCHEMBL2825781 | 0.67 | — | — | |
| Ammonia Solution, Strong SCHEMBL1793738 | 0.67 | EPHX1 (0.40) | ALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-2646411-B1 | PREPARATION OF PET PRECURSOR | BLUE EARTH DIAGNOSTICS LTD (GB) | 2017-08-16 | — | — | EP | claimed |
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | claimed |
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2025-04-22 | — | — | US | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-109563509-B | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs | 菲奥医药公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-1562932-B1 | 4-TETRAZOLYL-4-PHENYLPIPERIDINE DERIVATIVES FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | disclosed |
| US-20060217371-A1 | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20040152689-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE, S.A. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217371-A1 | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors | REN, ACE, ACE2 | ALDH1A1 1137/4885TSHR 2999/4885THRB 2946/4885 |
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | PTPN1, PTPN7, PTPN9 | ALDH1A1 3157/4885TSHR 2555/4885THRB 3505/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | ALDH1A1 391/4885TSHR 2730/4885THRB 2954/4885 |
| US-20040152689-A1 | Therapeutic agents useful for treating pain | OPRL1, OPRK1, OGFR | ALDH1A1 1831/4885TSHR 1034/4885THRB 291/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | ALDH1A1 795/4885TSHR 4635/4885THRB 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.